Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course aminoglycosides as adjunctive treatment in adults with sepsis
2021-001840-83Phase 4Terminated
- Sponsor
- University Medical Center Utrecht
- Start
- Jul 2021
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of gentamicin, tobramycin, cefuroxime and ceftriaxone in sepsis and bacterial disease (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: 30-day all-cause mortality. Started Jul 2021; status: terminated.
02
Drugs
gentamicintobramycincefuroximeceftriaxone
03
Conditions
sepsisbacterial disease
Beyond the preview
Go deeper on 2021-001840-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001840-83.